We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
(+75,773%)
Cap. Flow
+$169M
Cap. Flow
% of AUM
7.05%
Top 10 Holdings %
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tempest Therapeutics
TPST
|
+$94.4M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$24M |
| 3 |
AGN
Allergan plc
AGN
|
+$13.8M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$11.9M |
| 5 |
MBLY
Mobileye N.V.
MBLY
|
+$8.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$42.1M |
| 2 |
Gilead Sciences
GILD
|
+$11.5M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$11.1M |
| 4 |
Agilent Technologies
A
|
+$6.68M |
| 5 |
ADVM
Adverum Biotechnologies
ADVM
|
+$3.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 9.36% |
| 2 | Technology | 0.55% |
| 3 | Energy | 0.39% |
| 4 | Industrials | 0.16% |
| 5 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LUMO
26
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $22.1M | 0.92% |
+449
| New | +$174K |
|
27
PUT
Biogen
BIIB
$30.4B
| $21.7M | 0.9% |
514
+187
| +57% | +$73.7K |
|
|
RGLS
28
CALL
DELISTED
Regulus Therapeutics
RGLS
| $20M | 0.83% |
98
+6
| +7% | +$13K |
|
|
29
PUT
Gilead Sciences
GILD
$167B
| $18M | 0.75% |
1,832
-10,353
| -85% | -$1.05M |
|
30
PUT
Viatris
VTRS
$20.8B
| $17.8M | 0.74% |
+3,000
| New | +$171K |
|
|
GWPH
31
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $17.5M | 0.73% |
+1,923
| New | +$156K |
|
32
PUT
Puma Biotechnology
PBYI
$406M
| $15.3M | 0.64% |
648
+232
| +56% | +$49.6K |
|
|
AGN
33
PUT
DELISTED
Allergan plc
AGN
| $15M | 0.63% |
505
-501
| -50% | -$143K |
|
|
TSRO
34
CALL
DELISTED
TESARO, Inc.
TSRO
| $15M | 0.63% |
2,618
+2,084
| +390% | +$98.2K |
|
|
SGMO
35
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $14.7M | 0.61% |
9,384
-784
| -8% | -$12.1K |
|
|
IOC
36
PUT
DELISTED
Interoil Corporation
IOC
| $14.1M | 0.59% |
3,058
-1,423
| -32% | -$61K |
|
37
PUT
Community Health Systems
CYH
$393M
| $14M | 0.58% |
3,246
+1,338
| +70% | +$55.4K |
|
38
PUT
MannKind Corp
MNKD
$1.21B
| $12M | 0.5% |
4,610
+837
| +22% | +$25.2K |
|
|
ZGNX
39
DELISTED
Zogenix, Inc.
ZGNX
| $11.5M | 0.48% |
+1,052,351
| New | +$11.9M |
|
40
CALL
Ionis Pharmaceuticals
IONS
$9.14B
| $11.4M | 0.48% |
1,797
+588
| +49% | +$39.9K |
|
41
CALL
Celldex Therapeutics
CLDX
$2.79B
| $11.4M | 0.47% |
+272
| New | +$97.3K |
|
42
PUT
AbbVie
ABBV
$465B
| $11M | 0.46% |
1,884
+1,112
| +144% | +$67.2K |
|
|
THOR
43
CALL
DELISTED
THORATEC CORPORATION
THOR
| $10.2M | 0.43% |
2,439
+924
| +61% | +$35.3K |
|
44
CALL
Sarepta Therapeutics
SRPT
$1.63B
| $9.65M | 0.4% |
7,267
+695
| +11% | +$9.26K |
|
|
MBLY
45
DELISTED
Mobileye N.V.
MBLY
| $9.5M | 0.4% |
+226,080
| New | +$8.8M |
|
46
PUT
Teva Pharmaceuticals
TEVA
$36.9B
| $9.44M | 0.39% |
1,515
+34
| +2% | +$1.98K |
|
|
IOC
47
DELISTED
Interoil Corporation
IOC
| $9.36M | 0.39% |
202,932
-67,398
| -25% | -$2.89M |
|
|
48
PUT
Pfizer
PFE
$144B
| $9.29M | 0.39% |
2,814
-19,122
| -87% | -$608K |
|
49
Merck
MRK
$326B
| $9.24M | 0.38% |
168,418
-52,846
| -24% | -$2.99M |
|
50
Tenax Therapeutics
TENX
$419M
| $9.18M | 0.38% |
88
+15
| +21% | +$1.58M |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q1 2015 Portfolio in Review
As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.
By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.
- Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
- Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
- Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
- Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
- Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
- Sabby Management opened 126 new positions and closed 85 in Q1 2015.
- Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.
Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.